Freshly Printed - allow 10 days lead
Couldn't load pickup availability
Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics
A wide-ranging reference detailing the process of preclinical safety assessment of all types of biologics, including vaccines, biosimilars, novel biopharmaceuticals and more
Lisa Plitnick (Edited by), Danuta Herzyk (Edited by)
9780123948106, Elsevier Science
Hardback, published 29 August 2013
432 pages, 50 illustrations
23.4 x 19 x 2.8 cm, 1.07 kg
"…brings nonclinical testing of biological and follow-on biological drugs, vaccines plus cell and gene therapy drugs right up to date. It is written in a very readable, yet highly scientific manner and most of the relevant publications…on the topic are referenced…Overall, a ‘must read’ book for all in the nonclinical field of developing biological drugs." --btsNews, June 2014 "Researchers in pharmaceuticals, toxicology, and other biological sciences summarize the current status of developing medicines from biological material, pointing out where the process is different from developing small-molecule medicines and where it is the same. The topics include regulatory guidelines and their application in the non-clinical evaluation of biological medicines, early de-risking strategy for novel biotherapeutics…" --Reference & Research Book News, December 2013
Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics is a complete reference devoted to the nonclinical safety assessment of novel biopharmaceuticals, biosimilars, vaccines, cell and gene therapies and blood products. This book compares and contrasts these types of biologics with one another and with small molecule drugs, while incorporating the most current and essential international regulatory documents. Each section discusses a different type of biologic, as well as early characterization strategies, principles of study design, preclinical pharmacokinetics and pharmacodynamics and preclinical assays. An edited book that is authored by leading experts in the field, this comprehensive reference provides critical insights to all researchers involved in early through late stage biologics.
Preface Acknowledgement Dedication Section I: Biopharmaceuticals 1. Novel Biopharmaceuticals 2. Global Regulatory Guidances 3. Early de-risking strategies for Novel Biopharmaceuticals vs. Small Molecule Drugs 4. PK/PD assessments and Assays 5. Antibody-Drug Conjugates Section II: Biosimilar Therapeutics 6. Description of Biosimilar Therapeutics and Compare/contrast Biosimilar Therapeuticss and Novel Biopharmaceuticals 7. Global Regulatory Guidelines 8. Early characterization of Biosimilar Therapeutics vs. Novel Biopharmaceuticals/Studies Required and Principles of Study Design/PK/PD assessments/Assays Section III: Vaccines 9. Vaccines Description and Comparison/Contrast of Vaccines and Novel Biopharmaceuticals 10. Global Regulatory Guidances 11. Early de-risking strategies for Vaccines vs. Novel Biopharmaceuticals Section IV: Specialty Biologics and Indications 12. Cell Therapies 13. Gene Therapies 14. Blood Products 15. Oncology Drugs 16. Dual and Multi-Function Modalities 17. Stem Cell-Based Therapeutics
Subject Areas: Pharmaceutical technology [TDCW], Scientific standards [PDD], Medical toxicology [MMGT], Pharmacology [MMG]
